CYCC - Cyclacel slides on fadraciclib data in early-stage solid tumor study

Cyclacel dips ([[CYCC]] -10.3%) on average volume as investors appear underwhelmed with data from a Phase 1 study evaluating fadraciclib for solid tumors. Data were presented at EORTC-NCI-AACR Symposium24 heavily pretreated patients with various advanced solid tumors, were enrolled in part 2 with intravenous ((IV)) administration and five patients in part 3 with oral administration of the investigational drug.In completed part 1 of the study, target engagement and durable suppression of the MCL1 biomarker were observed after a single dose of fadraciclib by 4-hour infusion. Tumor shrinkage and stable disease were observed in five patients.In part 2 of the study, a heavily pretreated patient with MCL1 amplified endometrial cancer achieved a confirmed partial response after a month and a half on fadraciclib. This patient continues on therapy for more than a year and tumor lesions has reduced by 92%.An additional patient with cyclin E amplified ovarian cancer achieved stable disease with 29% tumor shrinkage.Part 3 is

For further details see:

Cyclacel slides on fadraciclib data in early-stage solid tumor study